Arbutus Biopharma Corp Business Combination, Contingent Consideration, Liability
Arbutus Biopharma Corp (ABUS) had Business Combination, Contingent Consideration, Liability of $6.67 million as of 2015-09-30, per its 10-Q filed 2015-11-05.
Discontinued › Balance Sheet › Liabilities
us-gaap:BusinessCombinationContingentConsiderationLiability · last filed 2015-11-05
- 2015-09-30: Business Combination, Contingent Consideration, Liability $6.67M.
- 2015-06-30: Business Combination, Contingent Consideration, Liability $5.14M.
- 2015-03-31: Business Combination, Contingent Consideration, Liability $4.74M.
| Period end | Business Combination, Contingent Consideration, Liability |
|---|---|
| 2015-09-30 | $6.67M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $5.14M 10-Q · filed 2015-08-07 |
| 2015-03-31 | $4.74M 10-Q · filed 2015-08-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |